Source: Eur Respir J, 58 (3) 2004522; 10.1183/13993003.04522-2020
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Mona Bafadhel, Neil Barnes, Stephen C. Bourke, Chris Compton, Gerard J. Criner, Mark T. Dransfield, David M.G. Halpin, MeiLan K. Han, Benjamin Hartley, C. Elaine Jones, Peter Lange, Sally Lettis, David A. Lipson, David A. Lomas, Neil Martin, Fernando J. Martinez, Robert Wise, Dave Singh. A single blood eosinophil count measurement is as good as two for prediction of ICS treatment response in the IMPACT trial. Eur Respir J, 58 (3) 2004522; 10.1183/13993003.04522-2020

Member's Comments

No comment yet.

Related content which might interest you: Analysis of IMPACT: is one blood eosinophil count measurement sufficient to predict ICS treatment response in COPD? Source: International Congress 2019 – COPD clinical trials: new molecules and novel insights Year: 2019 Response to omalizumab treatment according to blood eosinophil count: Results of a French real-world study (STELLAIR) Source: International Congress 2017 – Asthma: mechanisms and treatment Year: 2017 Cost-effectiveness of single-inhaler triple therapy for chronic obstructive pulmonary disease treatment by baseline blood eosinophil count: IMPACT trial Source: Virtual Congress 2021 – Difficult decisions on expected outcomes: availability of hospital resources and improvement of treatment adherence Year: 2021 Change in blood eosinophils following treatment with inhaled corticosteroids may predict long-term clinical response in COPD Source: Eur Respir J, 55 (5) 1902119; 10.1183/13993003.02119-2019 Year: 2020 Are peripheral blood eosinophil counts a guideline for omalizumab treatment? STELLAIR says no! Source: Eur Respir J, 51 (5) 1800730; 10.1183/13993003.00730-2018 Year: 2018 Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study Source: Eur Respir J, 51 (5) 1702523; 10.1183/13993003.02523-2017 Year: 2018 The blood eosinophil count as a biomarker in COPD Source: International Congress 2015 – Individualised risk reduction strategies for patients with COPD Year: 2015 Blood eosinophil count as a predictor of treatment response in adult patients with chronic cough Source: Virtual Congress 2020 – Asthma and cough: clinical trials and pharmacological insights Year: 2020 The reproducibility of COPD blood eosinophil counts Source: Eur Respir J, 52 (1) 1800427; 10.1183/13993003.00427-2018 Year: 2018 Late Breaking Abstract - Blood eosinophil count (EOS) can accurately predict responsiveness to inhaled corticosteroids (ICS) in COPD, but only if measured while patients are not receiving steroids. Source: International Congress 2018 – COPD: from LABA/ICS to LABA/LAMA/ICS Year: 2018 Asthma treatment based on sputum cell counts or usual clinical outcomes: the LOMA study Source: Eur Respir J 2003; 22: Suppl. 45, 35s Year: 2003 Clinical significance of blood neutrophil differential count in patients with COPD Source: International Congress 2017 – Biomarker-based asthma control Year: 2017 Peripheral blood eosinophil counts in COPD patients and its relationship with prescription of inhaled corticosteroid in real world setting in Japan. Source: International Congress 2017 – Airway disease and exacerbations Year: 2017 Low versus high Th2 asthma: variability of blood eosinophil counts in a longitudinal analysis Source: Virtual Congress 2021 – Severe asthma: evaluation using patient-reported outcome measures (PROMs) and biomarkers, comorbidities and treatments Year: 2021 High eosinophil counts predict decline in FEV1: results from the CanCOLD study Source: Eur Respir J, 57 (5) 2000838; 10.1183/13993003.00838-2020 Year: 2021 Automated cell differential count in sputum is feasible and comparable to manual cell count in identifying eosinophilia Source: International Congress 2019 – Research and innovation in airway diseases Year: 2019 Blood eosinophil (EOS) count, exacerbation rate and response to roflumilast in patients with severe COPD Source: International Congress 2017 – What is new in COPD management and prognosis: findings from large studies? Year: 2017 Long-term omalizumab treatment – do drug concentration levels count? Source: Virtual Congress 2020 – Personalised treatment of obstructive diseases Year: 2020 Accuracy of blood eosinophil count in predicting sputum eosinophils in children with problematic severe asthma (PSA) Source: Virtual Congress 2020 – Novel mechanisms and management of paediatric asthma Year: 2020 Impact of blood eosinophil variability in asthma: a real-life population study. Source: Virtual Congress 2021 – Clinical features and new biomarkers of asthma, COPD and chronic cough Year: 2021